Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
See Why Paul Prescott Has His Eyes On (NASDAQ: HYFT) Heading into This Morning—Wednesday, May 20, 2026
Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email.
My Full Coverage On (HYFT) is Starting Now
Get (HYFT) On Your Radar While It’s Still Early…
May 20, 2026
Most People Missed: (NASDAQ: HYFT) Last Night—The Bell Rings Soon, Here's the Story
Dear Reader, Street Ideas covers a lot of AI names. Most don't make the cut. The biologics discovery space in particular has become a magnet for platforms that look exciting from the outside — until you realize they're all working from the same flawed foundation: sequence-based systems that pattern-match across genetic text without ever understanding the functional biology beneath it. MindWalk Holdings Corp. (NASDAQ: HYFT) is not that story. HYFT® and LensAI™ operate at the conserved functional layer of biology — the layer where the subsequences that actually govern biological behavior live. While other platforms are reading biology, (HYFT) is working at the level where biology actually happens. The numbers are backing it up. Q3 FY 2026 revenue climbed 52% year-over-year. Three internal pipeline assets are advancing. A GLP-1 candidate just outperformed semaglutide in head-to-head in vitro testing. And as of right now, (HYFT) is sitting at the top of the Street Ideas watchlist heading into this morning’s session — Wednesday, May 20, 2026. According to Barchart, (HYFT) is currently triggering multiple bullish technical signals simultaneously: the 20 Day Moving Average, the 20–50 Day MA Crossover, and the 50 Day Moving Average. 
(HYFT) has made an approximate 40% move since late March 2026, touching $1.40 on May 11, according to history available from Barchart. According to TipRanks: Two analysts have recently set targets on (HYFT) which suggest 300% upside potential from its current range. 
When the technicals, the fundamentals, and the analyst targets are all pointing in the same direction simultaneously, that's worth paying attention to. With an approx. 40% move already on the board, 52% revenue growth, and analysts projecting 300% upside potential from current levels, (HYFT) is putting together exactly that kind of setup. Here's What Most People Don't Understand About Biologics AI — And Why (HYFT) Is Different
(HYFT) is a Bio-Native AI company focused on biologics discovery and AI-driven therapeutics development. Where conventional platforms apply machine learning to genetic sequences and hope the patterns hold, MindWalk's HYFT® biological pattern system and LensAI™ platform operate on something deeper: the invariant functional layer of biological sequence space — the conserved subsequences that are essential to biological function regardless of how much the surrounding sequence varies. This isn't a subtle technical footnote. It's the reason MindWalk can discover targets, candidates, and insights that sequence-based approaches simply cannot access. Think of it this way: two molecules can look completely different at the sequence level and still produce the same therapeutic effect, because what matters biologically is function, not letter order. MindWalk's LensAI™ platform is built to find exactly those connections — what the company calls "functional adjacency" — by linking molecular, structural, and functional data into a single traceable knowledge graph comprising more than 25B biological relationships. The company operates through three subsidiaries: MindWalk Biologics (Victoria, BC), BioStrand (Belgium), and Talem Therapeutics (North Dakota). 
Its biointelligence ecosystem covers antibody discovery and development, therapeutic antibodies, anti-ID/anti-dru-g antibodies, peptide therapeutics, vaccine programs, and diagnostics — all configured 1:1 to the client's specific program needs. The scientific credibility behind this platform is documented and searchable. More than 400 peer-reviewed publications and patents spanning two decades, and a discovery track record that places MindWalk at the origin of 21+ partner-owned dr-ug candidates — with 10 active clinical programs (Phase 1–3) now running at partners including Annexon Biosciences, argenx (NASDAQ: ARGX), Xencor (NASDAQ: XNCR), Cullinan Oncology, and Citryll BV. Major pharma relationships include Sanofi Pasteur and Janssen/J&J (Crucell). In March 2026, MindWalk launched B Cell Llama™, a nanobody discovery platform purpose-built for bispecific antibodies, multispecific therapeutics, and CAR-T therapies — backed by a peer-reviewed study in ACS Biomacromolecules demonstrating modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism. MindWalk holds the first right to commercialize jointly developed IP from this program. MindWalk’s Functional Biology Breakthrough
Here's what most people miss about the biologics discovery problem. Sequence-based AI tools — even very sophisticated ones — are fundamentally operating on a proxy for biology, not biology itself. Two sequences that look nothing alike can perform the same function. A mutation that changes a sequence dramatically might not change what the molecule does at all. And the targets that matter most therapeutically are often the ones that are conserved across variants, strains, and even species — precisely because evolution has locked them in place. MindWalk's HYFT® system is built to work at that functional layer. It identifies conserved subsequences — the biological "constants" — and maps the relationships between them across 25B+ data points in a traceable knowledge graph. Every insight is linked back to its biological evidence, which matters enormously for explainability in dr-ug development. This is not a faster version of what competitors are doing. It's a different kind of platform operating in a part of sequence space that others cannot access. 
The practical consequence of this is visible in the pipeline. MindWalk's Dengue program identified a single conserved epitope — one molecular target — across all 4 serotypes of the virus. This is the kind of problem that has resisted conventional approaches for decades, because sequence-based tools see four different viruses. (HYFT) sees one conserved functional constraint. The same logic applies to the Universal Influenza program, where the platform identified a single conserved functional constraint spanning influenza A, B, avian, and swine strains — simultaneously screening more than 2,000 diverse influenza sequences to find the biological constant hidden across all of them. And then there's the GLP-1 candidate. In head-to-head in vitro testing, MindWalk's molecule activated the GLP-1 receptor more effectively than semaglutide — and is additionally linked to a non-overlapping longevity pathway. These results, disclosed in the company's Q3 FY 2026 earnings presentation, place HYFT directly in the middle of one of the most closely watched therapeutic areas in biotech. MindWalk’s Discovery Engine at Work
One of the most underappreciated facts about (HYFT) is that its discovery engine has been validated — repeatedly, at scale, by some of the most demanding clients in life sciences — for two decades. The company's Discovery-to-Clinic overview documents what that actually looks like: Annexon Biosciences' ANX005 — a Phase 3 asset targeting Guillain-Barré Syndrome with FDA Breakthrough Therapy designation — traces its discovery origin to lead antibodies identified by MindWalk. argenx's ARGX-119, a first-in-class MuSK agonist antibody with Phase 2/3 trials planned for 2026, was selected from an anti-MuSK panel discovered at MindWalk. 
Xencor alone accounts for four distinct clinical-stage programs — Vudalimab (Phase 2), XmAb306 (Phase 1), XmAb808 (Phase 1), and others — all fed by a single MindWalk-generated hybridoma campaign. OncoResponse's OR502, now in active Phase 1/2 trials with a 65% disease control rate in initial data, was generated using MindWalk's proprietary B Cell Select® rabbit antibody platform. In every case, MindWalk sat at the most critical decision point in dr-ug development — the moment where target engagement is first demonstrated and the molecular series is born. Partners own the downstream clinical assets. But MindWalk is why those assets exist. Client testimony reflects this. Acumen Pharmaceuticals credited MindWalk's Rapid Prime immunization method as "pivotal" to identifying sabirnetug, now in Phase 2 trials. GentiBio noted that MindWalk's "customized discovery approach stood out immediately, and results from both their laboratory and LensAI platform exceeded expectations." These are not courtesy endorsements. They are assessments from scientists whose programs depended on the output. (HYFT)’s SaaS Story Takes Shape
According to the Q3 FY 2026 earnings release, MindWalk posted quarterly revenue of $4.2M CAD — up 52% year-over-year from $2.7M CAD in Q3 FY 2025. U.S. revenue doubled over the same period, with management attributing the growth directly to rising North American demand for AI-driven discovery. This is the third consecutive quarter of year-over-year revenue growth for (HYFT). The more structurally significant development may be the business model shift. During Q3, the company's largest in silico client signed a one-year annual enterprise LensAI™ platform contract — structured as recurring monthly revenue. Management described this as the model they are actively scaling. A fee-for-service antibody discovery lab transitioning toward a recurring-revenue SaaS platform built on a proprietary AI system represents a meaningful change in how the market should think about (HYFT)’s long-term economics. The company ended Q3 with $14.2M CAD in cash, with Netherlands divestiture proceeds being reinvested into growth and R&D. No public analyst price targets were available at time of publication.
BlackRock, Vanguard, and State Street Put Biologics AI in Focus
Here's something worth paying attention to. Antibody discovery and biologics AI platforms are attracting serious institutional capital — not just from specialist biotech funds, but from the largest asset managers in the world. OmniAb, Inc. (NASDAQ: OABI) — a comparable biologics discovery platform company — counts BlackRock, Inc., Vanguard Group, and State Street Corp. among its largest institutional shareholders, with 135 institutional owners collectively holding over 53M shares in the company. That kind of institutional presence in a niche biologics discovery name isn't accidental. These firms run exhaustive due diligence before establishing meaningful positions, and their presence signals a broader conviction that AI-native biologics discovery platforms represent durable, scalable value. (HYFT) operates in the same sector, with a technology argument that is arguably more differentiated — the functional layer approach is distinct from what OmniAb or most other platforms in this space are doing. As institutional awareness of this category grows, we’ll be keeping an eye out for little-known companies with defensible technology and documented commercial traction.. 7 Reasons (HYFT) is Our Top Watchlist Idea Heading Into Wednesday—May 20, 2026…1. Analyst Targets: Two analysts have recently set targets on (HYFT) that suggest 300% upside potential from its current range. 2. Revenue Growth: Q3 FY 2026 revenue for (HYFT) rose 52% year over year, reaching $4.2M CAD versus $2.7M CAD in Q3 FY 2025. 3. Recent Momentum: Since late March 2026, (HYFT) has already moved approximately 40%, touching $1.40 on May 11 per Barchart history.
4. Technical Signals: Multiple Barchart indicators are currently aligned for (HYFT), including the 20 Day Moving Average, 20–50 Day MA Crossover, and 50 Day Moving Average. 5. Clinical Validation: MindWalk’s discovery engine behind (HYFT) is tied to 21+ partner-owned candidates and 10 active clinical programs across Phase 1–3. 6. AI Differentiation: Rather than relying only on sequence data, (HYFT) uses HYFT® and LensAI™ to map conserved functional biology across more than 25B biological relationships. 7. Big Institutions Watching the Sector: Large asset managers including BlackRock, Vanguard, and State Street are cited as major holders in OmniAb, a comparable biologics AI platform, which gives (HYFT) a relevant sector backdrop. Get (HYFT) On Your Radar While It’s Still Early…
With accelerating revenue growth, expanding clinical validation, recurring LensAI™ platform revenue, and multiple technical indicators aligning at once, (HYFT) is becoming increasingly difficult to ignore. The combination of AI differentiation, active Phase 1–3 programs, and rising attention across the biologics AI category has placed (HYFT) firmly on our radar heading into this morning’s session. Get (HYFT) on your radar this morning—Wednesday, May 20, 2026. Don't head into today’s session without taking a look at (HYFT) first. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter
|
No comments:
Post a Comment